PLVAP, His, Human
PLVAP, His, Human

PLVAP, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

PLVAP, His, Human

Plasmalemma vesicle-associated protein (PLVAP, also called PV-1) is the only protein that forms endothelial diaphragms. PLVAP expression is very low in the normal blood-retinal barrier; however, pathological factors such as high glucose and vascular endothelial growth factor (VEGF) induce its expression, leading to the exacerbation of cellular permeability. Because the new blood vessels are fragile and leaky, PLVAP could possibly be considered a therapeutic target against retinovascular diseases.
Z05761
¥72,752.00

Ask us a question
Product Introduction
Species Human
Protein Construction
His PLVAP (Tyr49-Gly442)_x000D_
Accession # Q9BX97
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 45.97 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 50-70 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS, 200mM L-arginine (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • PLVAP, His, Human
    • PLVAP, His, Human

    PLVAP, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Plasmalemma vesicle-associated protein (PLVAP, also called PV-1) is the only protein that forms endothelial diaphragms. PLVAP expression is very low in the normal blood-retinal barrier; however, pathological factors such as high glucose and vascular endothelial growth factor (VEGF) induce its expression, leading to the exacerbation of cellular permeability. Because the new blood vessels are fragile and leaky, PLVAP could possibly be considered a therapeutic target against retinovascular diseases.
Synonyms FELS; PV1

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.